Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism.
We have examined whether degeneration of nigrostriatal dopaminergic neurons causes dysfunction of both the basal ganglia-thalamic and cerebello-thalamic pathways. Changes in the activity of thalamic neurons receiving input from the basal ganglia or the cerebellum were examined in two models of Parkinson's disease, 6-hydroxydopamine (6-OHDA)-lesioned rats and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys. Metabolic activity of the neurons was evaluated at the cellular level by quantitative in situ hybridization, using the expression of messenger RNA for subunit I of cytochrome oxidase (COI), encoded by the mitochondrial genome, as the marker. COI mRNA expression decreased significantly in thalamocortical neurons receiving input from the substantia nigra (-50.6%) or the cerebellum (-45%) in 6-OHDA-lesioned rats compared with controls. The decrease was observed in all thalamic neurons whether or not they were retrogradely labelled with a tracer injected into the motor cortex. Similarly, COI mRNA expression decreased in projection neurons and interneurons of the thalamus receiving input from the substantia nigra (-39 and -38%, respectively), the internal pallidum (-20 and -42.4%, respectively) and the cerebellum (-36.2 and -50%, respectively) of MPTP-treated monkeys compared with controls. These decreases in COI mRNA levels show that nigrostriatal denervation results in a decrease in the metabolic activity of thalamic neurons in the territories innervated by the substantia nigra, pallidum and cerebellum, which in turn is indicative of a decrease in their neuronal activity. The decrease did not concern the entire thalamus, however, since metabolic activity was unchanged in two thalamic nuclei considered to be limbic structures, the laterodorsal nucleus in 6-OHDA-lesioned rats and the anterior nucleus in MPTP-treated monkeys. Hypoactivity of both the basal ganglia-thalamic and cerebellar-thalamic pathways might therefore be implicated in the development of parkinsonian symptoms.
Rolland
Anne-Sophie
AS
INSERM, UMR679, Neurology and Experimental Therapeutics, Paris, France.
Herrero
Maria-Trinidad
MT
Garcia-Martinez
Virginia
V
Ruberg
Merle
M
Hirsch
Etienne C
EC
François
Chantal
C
D000818:Animals; D001479:Basal Ganglia / Q000378:metabolism*; D002531:Cerebellum / Q000378:metabolism*; D003342:Corpus Striatum / Q000201:enzymology; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D015259:Dopamine Agents; D003576:Electron Transport Complex IV / Q000032:analysis; D000882:Haplorhini; D007150:Immunohistochemistry / Q000379:methods; D017403:In Situ Hybridization / Q000379:methods; D007395:Interneurons / Q000378:metabolism; D009434:Neural Pathways / Q000378:metabolism; D009474:Neurons / Q000378:metabolism*; D016627:Oxidopamine; D010300:Parkinson Disease / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D013378:Substantia Nigra / Q000201:enzymology; D013565:Sympatholytics; D013788:Thalamus / Q000378:metabolism*; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis
D015259:Dopamine Agents; D012333:RNA, Messenger; D013565:Sympatholytics; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase; D003576:Electron Transport Complex IV; D004298:Dopamine